The broad market had a rough Wednesday, but Thursday morning produced a cleaner pocket of strength outside technology: healthcare companies that beat expectations and backed the move with better guidance or strong product demand.
The useful distinction is not simply “earnings beat.” The stronger setups combined a price reaction with evidence that could persist beyond one quarter.
Market snapshot
Latest reliably verified completed U.S. session: Wednesday, July 29, 2026, at the 4:00 p.m. ET close.
- S&P 500: 7,316.15, down 1.5%
- Dow Jones Industrial Average: 51,594.14, down 2.2%
- Nasdaq Composite: 24,442.94, down 1.7%
- Brent crude settled above $88 a barrel after a sharp geopolitical rise.
The stock moves below were reported in premarket trading between approximately 7:00 and 7:54 a.m. ET on July 30. Intraday prices can change quickly, so this article does not substitute unverified live quotes for confirmed figures.
1. Baxter: the clearest earnings-gap setup
Premarket move: about +14%.
Catalyst and evidence
Baxter raised its 2026 adjusted earnings forecast to $1.95–$2.15 per share, from $1.85–$2.05. Quarterly adjusted earnings of $0.56 per share beat the $0.37 estimate, while revenue of $2.96 billion topped the $2.80 billion estimate.
Its largest medical-products segment grew sales by 7%, supported by demand for IV solutions and drug compounding. That combination—revenue beat, profit beat and higher guidance—makes the reaction more credible than a rally driven only by cost cutting.
Main risk
Baxter still has a hold on shipments and installations of its Novum infusion pump, expected to continue through 2026. Weak infusion-system sales could limit the turnaround.
Invalidation condition
The momentum case weakens if the stock gives back most of the earnings gap or if subsequent guidance shows IV-solution strength cannot offset the pump disruption.
2. Regeneron: product growth, not just expense control
Premarket move: nearly +5%.
Catalyst and evidence
Regeneron reported quarterly revenue of $4.29 billion, up 17% and ahead of the $3.82 billion estimate. Adjusted profit of $14.29 per share also beat the $10.26 estimate.
The important part was product demand. Global Dupixent sales rose 38% to about $6 billion, while U.S. sales of high-dose Eylea increased 52% to $596 million. This is a stronger momentum signal than a narrow earnings beat because the growth came from major commercial products.
Main risk
Lower-dose Eylea remains under competitive and pricing pressure. Regeneron also depends heavily on a relatively concentrated group of medicines.
Invalidation condition
Watch whether the stock holds the post-results gap and whether high-dose Eylea and Dupixent continue growing fast enough to offset erosion elsewhere in the portfolio.
3. Bristol Myers Squibb: a guidance reset with an old-drug problem
Premarket move: as much as +2.5%.
Catalyst and evidence
Bristol Myers raised its full-year revenue forecast to $49–$50 billion, from $46–$47.5 billion, and lifted adjusted earnings guidance to $6.75–$7.00 per share, from $6.05–$6.35.
Quarterly revenue reached $12.97 billion, above the $11.75 billion estimate, while adjusted earnings of $2.04 per share beat the $1.59 estimate. Eliquis sales rose 22% to $4.48 billion, and several newer medicines exceeded expectations.
Main risk
The legacy portfolio is still shrinking. Revlimid sales fell 49%, and Opdivo sales declined 3%. The market needs evidence that newer products can replace those losses rather than merely soften them.
Invalidation condition
The setup deteriorates if investors reject the higher guidance after the open, or if future quarters show that growth medicines are not scaling quickly enough to cover patent and generic pressure.
The quick ranking
For short-term momentum quality, the order is:
- Baxter — strongest price reaction plus a broad beat and guidance raise.
- Regeneron — strongest underlying product-growth evidence.
- Bristol Myers — meaningful guidance upgrade, but with heavier legacy-drug risk.
The broader lesson is simple: in a volatile market, prefer companies where the catalyst changes the forward earnings picture. A large one-day gain without better revenue, guidance or product demand is easier to reverse.
Conclusion
Healthcare was not uniformly strong—some companies fell despite apparently good headline numbers—but Baxter, Regeneron and Bristol Myers showed credible, company-specific momentum. The next test is whether buyers defend the earnings gaps after the opening excitement fades.
This article is for educational purposes only and is not financial advice. Premarket moves are volatile, reported prices may differ from later trading, and any investment can lose value.